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Abstract Cannabis use disorder (CUD) co-occurs with
major depressive disorder (MDD) more frequently than
would be expected by chance. However, studies to date
have not produced a clear understanding of the mechanisms
underlying this co-morbidity. Genetically informative studies can add valuable insight to this problem, as they allow
the evaluation of competing models of co-morbidity. This
study uses data from the Australian Twin Registry to compare 13 co-morbidity twin models initially proposed by
Neale and Kendler (Am J Hum Genet 57:935–953, 1995).
The analysis sample comprised 2410 male and female

monozygotic and dizygotic twins (average age 32) who
were assessed on CUD and MDD using the SSAGA-OZ
interview. Data were analyzed in OpenMx. Of the 13 different co-morbidity models, two fit equally well: CUD
causes MDD and Random Multiformity of CUD. Both fit
substantially better than the Correlated Liabilities model.
Although the current study cannot differentiate between
them statistically, these models, in combination, suggest
that CUD risk factors may causally influence the risk to
develop MDD, but only when risk for CUD is high.
Keywords Co-morbidity · Major depressive disorder ·
Cannabis use disorder · Twin model · Genetics
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Introduction
Major depressive disorder (MDD) and Cannabis use disorder (CUD) are co-morbid (see Degenhardt et al. 2012) and
highly relevant from a public health perspective. According to the latest Global Burden of Disease study in 2013,
MDD was the 2nd leading cause of disability in the world
(Ferrari et al. 2013), and the World Health Organization
is now citing it as the leading one (WHO 2016). Heavy
cannabis use is linked to several adverse health outcomes
(Hall and Degenhardt 2009; Hall 2015), and is the most
commonly used illicit drug (Agrawal and Lynskey 2014).
The relationship between MDD and CUD is poorly understood, although individuals with co-morbid mental health
and substance use disorders are particularly difficult to treat
(Kessler 2004). Developing a greater understanding of the
relationship between CUD and MDD is therefore important
in order to help reduce the prevalence of both conditions
through the efficient prevention and treatment of co-morbid
cases.
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Cross-sectional studies of general and clinical populations consistently show that CUD and MDD co-occur at a
rate greater than chance (see Degenhardt et al. 2012 for a
review). For instance, an epidemiological study of 43,093
US citizens showed that individuals with mood disorders
(MDD, dysthymia, mania, hypomania) had 3.9 (95% CI
2.8–5.3) times higher odds of meeting criteria for lifetime
cannabis abuse and dependence (Martins and Gorelick
2011). An epidemiological survey of 25,113 Canadian citizens reported that rates of past-year cannabis dependence
among individuals who met 12 month MDD criteria were
over 7.25 times higher compared to those who did not (Patten et al. 2015). Rates of past-year abuse were almost 3.6
times higher (Patten et al. 2015). Similar results have been
found in clinical samples. For example, a recent study based
on the Norwegian patient registry including 2,659,966 individuals, reported that levels of ICD-10 depressive illness
were almost 3.9 times higher among individuals with CUD
(12.85%), compared to the general population (3.3%, Nesvåg et al. 2015).
There have been several attempts, including longitudinal
and genetic studies, to explain this pattern of co-morbidity.
Most longitudinal studies have looked at the relationship
between MDD and cannabis use, rather than CUD. Studies investigating non-heavy cannabis use have not been able
to establish a clear causal link in either direction (e.g. LevRan et al. 2014; Feingold et al. 2014; Cougle et al. 2015;
Danielsson et al. 2016). However, heavy cannabis use is
more consistently and more strongly associated with MDD.
In a meta-analysis Lev-Ran et al. (2014) found a moderate
(OR 1.62, 95% CI 1.21–2.16) increase in risk of developing depressive disorders following heavy cannabis use. The
strongest statistically significant relationships have been
observed between clinical levels of cannabis use and MDD,
with cannabis abuse preceding MDD (OR 4.00, 95% CI
1.23–12.99, Bovasso 2001) and CUD preceding MDD (OR
2.54, 95% CI 1.40–4.60, Marmorstein et al. 2012). However, there is also some evidence of a bidirectional relationship, from baseline CUD to incident MDD (OR 1.78,
95% CI 1.17–2.71), as well as baseline MDD to incident
CUD (OR 2.28, 95% CI 1.28–4.05; Pacek et al. 2013),
while other studies have found no significant relationships
(Harder et al. 2008; Feingold et al. 2014).
Overall, causal influences, mainly from CUD to MDD,
may be present, but clear conclusions are precluded by
the heterogeneity among studies, particularly in terms of
the control for confounding factors. Feingold et al. (2014)
found that cannabis users and non-users differed significantly on age, gender, household income and marital status. An early study by Fergusson and Horwood (1997) also
demonstrated differences on a large number of factors,
including childhood adversities, social disadvantage, contact with peers who engaged in substance use or delinquent
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behaviors, and psychological adjustment problems. Establishing causality in either direction therefore still requires
further evidence.
Previous twin studies investigating this co-morbidity
have been scarce, and offered mixed evidence. In a discordant twin study by Lynskey et al. (2004), there was a significant genetic correlation between cannabis dependence
and MDD (men, r = 0.44, 95% CI = 0.17–1.00; women,
r = 0.69, 95% CI 0.30–1.00), but cannabis dependence was
not a unique causal factor for MDD. Among MZ twins
discordant for cannabis dependence, the dependent twins
did not have greater odds for MDD (OR 1.16, 95% CI
0.64–2.17). Lynskey et al. (2004) also found no evidence
of causality in the opposite direction (OR 1.38, 95% CI
0.55–3.42). In contrast, Lin et al. (1996) reported that MZ
twins with MDD were more likely to be cannabis dependent (OR 2.3, 95% CI 1.1–4.7), compared to their co-twins
without MDD. Differences in results between these studies might be explained by differences in their samples. Lin
et al.’s (1996) analysis sample, i.e. twins discordant for
lifetime MDD, comprised 234 male veterans twin pairs,
while Lynskey et al. (2004) examined a sample of 156 twin
pairs from the general population, including both male and
female same-sex twins. Additionally, Fu et al. (2002) found
that antisocial personality disorder explained 62% of the
genetic correlation between CUD and MDD in a multivariate twin study.
This mixed evidence suggests that the exact nature of
the relationship between CUD and MDD warrants further
study. One possibility to comprehensively investigate competing models of co-morbidity is to fit Neale and Kendler’s
(1995) 13 co-morbidity models, which were based on the
work of Klein and Riso (1993). Each model and each class
of models makes different assumptions about the etiological mechanisms that lead to the co-morbidity. Four broad
classes are examined: single liability, independent liability,
multiformity and correlated liabilities. No other twin model
approach examines such a large variety of model classes.
If the co-morbid form arises from a single liability shared
by CUD and MDD, the diagnostic boundary between MDD
and CUD may have been artificially drawn, and they could
be alternate forms of the same disorder. Alternatively, liability to the co-morbid form may be entirely independent:
co-morbidity arises due to a third disorder, unrelated to the
pure forms of MDD and CUD. Multiformity models suggest that the risk factors for CUD and MDD are unrelated,
but once certain thresholds on the liability of one disorder
are crossed, the risk of symptoms of the other disorder
increases sharply. In other words, MDD and CUD influence
each other in a discontinuous way, only once certain levels
of risk are reached. In contrast, correlated liabilities models assume that liabilities between two disorders are related
continuously, and etiological factors overlap. Any change
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in risk for one disorder is accompanied by a change in risk
for the other disorder, whether this is due to shared risk factors or causality. In addition, the models test whether the
co-morbidity observed in the population has occurred by
chance.
The NK comorbidity models have been used to examine the relationship between a range of other substance-use
phenotypes (Agrawal et al. 2004, 2007, 2010). Twin models of co-morbidity would also be a useful tool to study the
relationship between cannabis involvement and depression
(Agrawal and Lynskey 2014), as both MDD (e.g. Sullivan
et al. 2000; Kendler et al. 2006a) and cannabis dependence
(Lynskey et al. 2002; Verweij et al. 2010) are influenced by
genetic factors.
To date, no study has examined all 13 models with
respect to these phenotypes, although previous longitudinal
and twin studies have produced conflicting findings regarding the relationship between MDD and CUD. Therefore,
the current study aimed to fit all 13 NK co-morbidity models to examine the relationship between CUD and MDD
in a cross-sectional sample of 2410 Australian twins born
between 1972 and 1979.

Methods
Participants
From a sample of 4131 twin pairs included in the Australian Twin Registry, 3824 twins and non-twin siblings born
between 1972 and 1979 were interviewed on cannabis use,
related drug use and other psychopathology (see Lynskey
et al. 2012 for further details of the sample). The analyses presented in this paper were conducted on twins only
and required complete data from each twin pair for both
phenotypes. Consequently, 2410 individual twins were
included in the analysis sample: 565 (396 female, 169
male) complete MZ pairs and 640 (298 female–female, 118
male–male and 224 female–male) complete DZ twin pairs.
The mean age of the sample was 32 years.
Measures
SSAGA‑OZ interview
Computer-assisted telephone interviews based on the
Australian version of Semi-Structured Assessment of
the Genetics of Alcoholism (SSAGA-OZ; Bucholz et al.
1994) were used to assess twins on several variables. The
SSAGA-OZ has been widely used in family studies of
alcohol dependence and collects detailed information on
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patterns of DSM-IV (American Psychiatric Association
2000) symptomatology across a range of mental health
and substance use disorders. Assessments of these disorders, including MDD and CUD, have been shown to
have good reliability and validity (Bucholz et al. 1994).
In order to keep the measures comparable to current literature, items were coded as close to DSM-5 (American
Psychiatric Association 2013) as the available information allowed. Although coding the phenotypes as binary
variables reduces statistical power, the co-morbidity
models were developed for and can currently only be fitted to binary data.
Cannabis Use Disorder: Participants were assessed
on DSM-IV Cannabis Abuse/Dependence criteria. Abuse
items included “hazardous use”, “social/interpersonal
problems related to use”, “neglecting major roles to use”
and “legal problems”. Dependence items included “tolerance”, “using larger amounts or using longer”, “repeated
attempts to quit or control use”, “much time spent using”,
“physical or physiological problems related to use”, and
“activities given up to use”. In addition, an assessment
of cannabis withdrawal was available (see Verweij et al.
2013). However, no assessment of “craving”, a criterion introduced in DSM-5, was available for this sample.
CUD was coded as a binary phenotype. To approximate
DSM-5 criteria, individuals were coded as 1 (“affected”)
if they reported at least 2 symptoms of DSM-5 CUD,
except for “craving”. The remaining participants were
coded as 0 (“unaffected”), whether or not they reported
a lifetime history of cannabis use. The “legal problems”
criterion was removed from DSM-5 and therefore was not
included in our definition of CUD.
Major Depressive Disorder: Participants were
assessed on the following DSM-IV symptoms of
MDD: “depressed or irritable mood”, “loss of pleasure”, “change in appetite or weight”, “change in sleep”,
“energy loss or fatigue”, “change in psychomotor activity”, “feelings of guilt or worthlessness”, “difficulty concentrating or making decisions”, and “suicidal ideation”.
MDD was also coded as a binary phenotype. The participant was coded as 1 (“affected”) if they experienced 5
or more of the above symptoms for over 2 weeks, including depressed/irritable mood or loss of pleasure. Participants were not coded as having MDD if they met the
following exclusion criteria: (i) their symptoms did not
affect functioning in any area of life, or (ii) they occurred
within 2 months of bereavement, (iii) within 1 month of
using tranquilizers, blood pressure medication or steroids, or (iv) just after having used illegal drugs, alcohol
or tobacco. As there have been no major changes in the
diagnostic criteria for MDD between DSM-IV and DSM5, the coding was representative of DSM-5 MDD.

Behav Genet (2017) 47:394–404
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Statistical models
A summary of all models can be found in Table 1. Each
model makes different assumptions about the way in
which co-morbid cases arise. A detailed discussion of
each model can be found in Neale and Kendler (1995)
and Rhee et al. (2004).
Because both phenotypes were coded as binary variables, the foundation of each co-morbidity model was a
normal liability threshold model, which is based on the
multifactorial theory of inheritance (Falconer 1965).
Similar to widely used liability threshold models, all
models estimate genetic (A), shared (C) and non-shared
environmental (E) factors. D was not estimated in the
current sample, because the difference between MZ and
DZ correlations indicated an ACE model. However, there
are several important differences between models:

1. The models differ in the number of liability distributions they assume. For instance, the Alternate Forms
model assumes that both phenotypes arise from one
distribution of liability. In contrast, the Three Inde‑
pendent Disorders model assumes that there are three
underlying liability distributions. Two of those give
rise to the pure forms of the phenotypes, and one gives
rise to the co-morbid form.
2. The models differ in the way in which the above-mentioned liabilities produce the phenotype. For example,
in the Alternate Forms model, an individual develops
co-morbid CUD and MDD by crossing the threshold
on the shared liability distribution. However, in the
Three Independent Disorders model, an individual can
develop CUD and MDD if they cross the threshold on
the CUD-specific and MDD-specific distribution at the
same time, or if they do so on the liability distribution
for the co-morbid form.

Table 1  Summary and interpretation of Neale and Kendler (1995) models of co-morbidity
Nr. Model
1
2

3

4
5
6

7
8
9
10
11
12
13

Sub-models

Description applied to CUD and MDD

Alternate forms

Single liability: after crossing a common threshold, some develop CUD,
some MDD. MDD and CUD are alternate forms of the same disorder
Three independent disorders
Pure forms are unrelated disorders. Three independent liabilities for CUD,
MDD and co-morbid CUD with MDD
Multiformity
The liabilities for CUD and MDD are unrelated. CUD discontinuously
increases the risk of MDD symptoms, and vice versa when thresholds are
crossed. Random multiformity assumes one, extreme multiformity two
thresholds
Random multiformity (RM)
Assumes a single threshold within one disorder (e.g. CUD), above which
the risk to develop symptoms of the other disorder (e.g. MDD) suddenly
increases. This model allows for both disorders to increase the risk of
symptoms of the respective other
RM of MDD
Being above the threshold for MDD risk leads to a sudden increase in risk
for symptoms of CUD, even when below the threshold for CUD
RM of CUD
Being above the threshold for CUD risk leads to a sudden increase in risk for
symptoms of MDD, even when below the threshold for MDD
Extreme multiformity (EM)
There are two distinct thresholds for both disorders. Crossing the 1st threshold leads to the pure form of a disorder. The 2nd threshold allows for individuals with high amounts of risk factors. Individuals will be at increased
risk for symptoms if they are above the 2nd threshold (at increased risk) for
either disorder
EM of MDD
Being above the 1st threshold for MDD risk only leads to MDD. A proportion of high-risk individuals with MDD (above the 2nd threshold) develop
CUD symptoms, even when below the 1st threshold for CUD
EM of CUD
Being above the 1st threshold for CUD risk only leads to CUD. A proportion
of high-risk individuals with CUD (above the 2nd threshold) have MDD
symptoms, even when below the 1st threshold for MDD risk
Correlated liabilities
Correlation between latent genetic and environmental influences on CUD
and MDD gives rise to co-morbidity
Reciprocal causation
Liability for CUD has causal influence on liability to experience MDD, and
vice versa
Unidirectional: MDD to CUD Liability to experience MDD has causal influence on liability for CUD
Unidirectional: CUD to MDD Liability to experience CUD has causal influence on liability for MDD
Chance
Co-morbid CUD and MDD occur due to chance alone
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3. One model, the Extreme Multiformity Model, also
differs from all others in the number of thresholds it
assumes. Under the assumptions of this model, each
liability distribution has two thresholds. If an individual crosses the first threshold, they only develop the
pure form of a disorder. Crossing the second threshold means that the individual develops the co-morbid
form. Consequently, co-morbidity arises if an individual crosses the first threshold on both liability distributions, the second threshold on one liability distribution
(e.g. CUD), and/or the other distribution (e.g. MDD).

minimize the difference between the observed number of
cases in each co-morbidity category and the expected number according to the model. A chi-squared goodness-of-fit
(χ2) test compared these observed and expected values, and
indicated model fit. The p value of the χ2 test was used to
reject models whose predicted data was significantly different from the observed data. The best fitting and most parsimonious model was chosen based on the Akaike Information Criterion (AIC; Akaike 1987). According to Burnham
and Anderson (2002) an AIC difference of 3 and over indicates that the model with the lower AIC has substantially
more support.

Data analysis

Results

Data analysis was conducted using OpenMx (Neale et al.
2016) for R statistical software (R Core Team 2014). The
input to each model was a frequency table, which summarized the number of twin pairs fitting into 10 MDD-CUD
co-morbidity categories (see Table 2). Each twin pair
member was assigned to one of four disease state categories: MDD but no CUD (i.e. 1 0), no MDD, but CUD (i.e.
0 1), both MDD and CUD (i.e. 1 1), and neither (i.e. 0 0).
Thereafter, twin disease states were combined (i.e. 0 0
0 1). Although there are 16 different combinations of cotwin disease states, information about twin order was disregarded to avoid low cell counts. For instance, “0 0 1 0”
(see Table 2) is a category that contains cases where twin 1
only (i.e. 1 0 0 0) or twin 2 only (i.e. 0 0 1 0) was affected
by MDD. Subsuming all replicating disease states resulted
in ten categories.
For every model, the number of twin pairs expected in
each of the 10 categories was based on the assumptions of
the model. Maximum likelihood estimation was used to
Table 2  Number of twin
pairs in co-morbidity status
categories

In the analysis sample, 15.4% (11.9% of females, 22.6% of
males) met criteria for lifetime CUD and 26.1% (29.5% of
females, 19.2% of males) met criteria for lifetime MDD.
Females had a significantly higher prevalence of MDD (OR
1.77, 95% CI 1.44–2.17) and lower prevalence of CUD
(OR 0.46, 95% CI 0.37–0.58). CUD was almost twice as
frequent in individuals with lifetime MDD (24.3%), compared to those without (12.3%). The odds ratio, adjusted for
sex and age, was 2.66 (95% CI 2.10–3.37).
A conditional logistic regression of MZ twin pairs discordant for CUD showed that MZ twins with CUD had significantly elevated rates of MDD (46.0%) relative to their
co-twin who did not have CUD (28.12%; OR 2.83, 95% CI
1.12–7.19; N = 63 MZ pairs).
The model-fitting results are summarized in Table 3.
In addition to the 13 co-morbidity models, we included a
saturated model based on twin correlations for comparison.
Five models can be rejected, due to the large, statistically

Twin 1

1
2
3
4
5
6
7
8
9
10
Total

Twin 2

MDD

CUD

MDD

CUD

0a
0
0
0
0
0
0
1
1
1

0
0
0
0
1
1
1
0
0
1

0
0
1
1
0
1
1
1
1
1

0
1b
0
1
1
0
1
0
1
1

Used as input for all co-morbidity models

a

b

13

0 unaffected
1 affected

MZ

DZ

298
28
114
17
16
6
16
47
12
11
565

277
73
145
35
10
21
23
33
18
5
640
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Table 3  Co-morbidity model fit statistics and questions models aim to address
Model
Saturated Model
1
Alternate Forms
2
Three Indep. Disorders
3
Random Multiformity
4
RM of MDD
5
RM of CUD
6
Extreme Multiformity
7
EM of MDD
8
EM of CUD
9
Correlated Liabilities
10
Reciprocal Causation
11
MDD causes CUD
12
CUD causes MDD
13
Chance

Question

χ2

Df

p

AIC

Alternate forms of the same disorder?
Co-morbid form is an independent disorder?
Abruptly increase symptoms of each other?
MDD abruptly increases CUD symptoms?
CUD abruptly increases MDD symptoms?
Abruptly increase symptoms of each other in extreme cases?
MDD abruptly increases CUD symptoms in extreme cases?
CUD abruptly increases MDD symptoms in extreme cases?
Liabilities are correlated?
CUD and MDD cause each other?
MDD causes CUD?
CUD causes MDD?
Co-morbid due to chance?

13.16
96.31
32.90
15.10
27.04
15.46
16.32
28.23
19.50
15.21
15.23
17.86
15.50
59.46

11
14
8
10
11
11
10
11
11
9
10
11
11
12

0.283
<0.001
<0.001
0.129
0.004
0.162
0.091
0.003
0.053
0.085
0.124
0.085
0.161
<0.001

−8.84
68.31
16.90
−4.90
5.04
−6.54
−3.68
6.23
−2.50
−2.79
−4.77
−4.14
−6.50
35.46

significant differences between the observed cell counts
within the co-morbidity categories (see Table 2) and the
cell counts expected under the model: the Chance, Alter‑
nate Forms, Three Independent Disorders, RM of MDD,
and EM of MDD models.
The only models that do not have substantially less support than the saturated model (i.e. an AIC difference larger
than 3) are the RM of CUD (model 5) and CUD causes
MDD (model 12) models (see Fig. 1a, b), with differences
of 2.30 and 2.34 respectively. Both models have substantially more support than the Correlated Liabilities model.
These two best fitting models are, however, not substantially different from some of the models within their
class. The RM of CUD model is not substantially different from the Random Multiformity model. The CUD

causes MDD model is not substantially different from
the MDD causes CUD and Reciprocal Causation model.
Additionally, both models do not substantially differ from
the Extreme Multiformity model.
In the best fitting models both CUD and MDD are
influenced by genetic and non-shared environmental factors. In the case of CUD, 79–80% of the total variance is
estimated to be explained by genetic factors and 20–21%
by non-shared environmental factors. For MDD, 43–48%
of the total variance is explained by genetic, 52–57% by
non-shared environmental factors. Model-fit did not significantly deteriorate when C was dropped from both
models. Parameter estimates from all models can be
found in Table 4.

Fig. 1  Parameter estimates from best fitting co-morbidity models: a Random Multiformity of CUD, b Causation—CUD causes MDD. r probability of MDD phenotype if above threshold on CUD liability, iCUD regression coefficient, *Significant at the 0.05 level

13

13

–

–

–
–
−0.31

tMDD
tCUD
tshared

–
0.10(0.06–
0.14)
–

–
0.02(0.02–
0.08)
0.20(0.09–
0.27)
–

0.71
1.01
–

–

–

–

0.64
1.06
–

–

–

0.46(0.23–
0.57)
0.00(0.00–
0.17)
0.54(0.43–
0.66)
0.86(0.53–
0.94)
0.03(0.00–
0.31)
0.12(0.06–
0.21)
–

4

0.48(0.20–
0.60)
0.00(0.00–
0.22)
0.52(0.40–
0.65)
0.82(0.52–
0.90)
0.00(0.00–
0.24)
0.18(0.10–
0.29)
–

3

0.72
0.99
–

–

0.22(0.15–
0.29)
–

–

–

–

0.48(0.19–
0.60)
0.00(0.00–
0.23)
0.52(0.40–
0.64)
0.80(0.50–
0.87)
0.00(0.00–
0.24)
0.20(0.13–
0.31)
–

5

0.69; 2.21
1.04; 1.98
–

–

–

–

–

–

–

0.48(0.17–
0.59)
0.00(0.00 –
0.35)
0.52(0.41–
0.65)
0.74(0.41–
0.83)
0.01(0.00–
0.28)
0.25(0.17–
0.36)
–

6

0.64; 1.92
1.07
–

–

–

–

–

–

–

0.46(0.23–
0.56)
0.00(0.00–
0.45)
0.54(0.44–
0.66)
0.76(0.45–
0.87)
0.03(0.00–
0.29)
0.21(0.13–
0.31)
–

7

0.72
1.00; 1.81
–

–

–

–

–

–

–

0.48(0.17–
0.59)
0.00(0.00–
0.08)
0.52(0.41–
0.65)
0.74(0.41–
0.83)
0.01(0.00–
0.28)
0.25(0.17–
0.36)
–

8

0.64
0.99
–

–

–

–

0.45(0.18–
0.56)
0.01(0.00–
0.21)
0.56(0.44–
0.67)
0.79(0.48–
0.87)
0.01(0.00–
0.26)
0.20(0.13–
0.31)
0.19(–0.03–
0.31)
0.01(−.07–
0.17)
0.08(−0.01–
0.17)
–

9

07(−0.19–
0.32)
21(−0.05–
0.52)
0.66
1.01
–

–

–

–

–

0.44(0.19–
0.55)
0.00(0.00–
0.14)
0.56(0.45–
0.70)
0.80(0.48–
0.88)
0.00(0.00–
0.03)
0.20(0.12–
0.30)
–

10

0.64
1.03
–

0.26(0.18–
0.35)

–

–

–

–

0.47(0.22–
0.57)
0.00(0.00–
0.19)
0.53(0.43–
0.65)
0.81(0.52–
0.88)
0.00(0.00–
0.23)
0.19(0.12–
0.30)
–

11

0.28(0.20–
0.38)
0.66
.0.99
–

–

–

–

–

–

0.43(0.18–
0.54)
0.00(0.00–
0.18)
0.57(0.46–
0.70)
0.79(0.79–
0.87)
0.00(0.00–
0.26)
0.21(0.13–
0.32)
–

12

0.63
0.96
–

–

–

–

–

–

0.46(0.23–
0.56)
0.00(0.00–
0.18)
0.54(0.44–
0.66)
0.76(0.45–
0.87)
0.03(0.00–
0.29)
0.21(0.13–
0.31)
–

13

p probability of CUD if above threshold on the MDD liability (models 3–5), or above threshold on the shared liability (model 1), r probability of MDD if above threshold on the CUD liability
(models 3–5), or above threshold on the shared liability (model 1), iCUD regression coefficient from CUD to MDD, iMDD regression coefficient from MDD to CUD, tMDD threshold for MDD,
tCUD threshold for CUD

Model numbers refer to co-morbidity models outlined in Table 1. Shared a2, c2 and e2 refer to the single shared liability in model 1, third independent liability in model 2, or Cholesky paths
from MDD to CUD in model 9

0.63
0.96
1.13

–

iCUD

–

e2CUD

–

–

c2CUD

0.46(0.23–
0.56)
0.00(0.00–
0.17)
0.54(0.44–
0.66)
0.76(0.45–
0.87)
0.03(0.00–
0.29)
0.21(0.13–
0.31)
0.53(0.00–
1.00)
0.02(0.00–
1.00)
0.45(0.00–
1.00)
–

2

a2shared 0.66(0.66–
0.66)
c2shared 0.34(0.34–
0.34)
e2shared 0.00(0.00–
0.00)
p
0.44(0.44–
0.44)
r
0.27(0.27–
0.27)
iMDD –

–

a2CUD

e2MDD –

c2MDD –

a2MDD –

1

Model

Table 4  Parameter estimates of all co-morbidity models for MDD and CUD
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Discussion
To our knowledge, this study is the first to fit the 13 comorbidity models proposed by Neale and Kendler (1995) to
cannabis use disorder and major depressive disorder. Both
epidemiological and discordant twin analyses confirmed
that these models were appropriate for the current sample.
In line with other cross-sectional studies (see e.g. Degenhardt et al. 2012) epidemiological analyses showed that
CUD and MDD were significantly co-morbid. Discordant twin analyses, which will be discussed further below,
showed that causal processes could not be excluded as an
explanation for this co-morbidity, because MZ twins with
CUD were significantly more likely to display symptoms
of MDD than their co-twin without CUD. Therefore, there
was sufficient reason to further explore causality in the comorbidity model analyses.
The two best-fitting models were Random Multiformity
of CUD and CUD causes MDD. Both models fit substantially better than the Correlated Liabilities model, and not
substantially worse than the Saturated model. In addition,
five models could be statistically rejected: the Alternate
Forms, Chance, Three Independent Disorders, RM of MDD
and EM of MDD models. The heritability estimates in the
best fitting models range from 79 to 80% for CUD and 43
to 49% for MDD.
Model‑fitting
These model-fitting results suggest that the direction of
effect goes from CUD to MDD. Firstly, both RM of MDD
and EM of MDD can be statistically rejected. It seems plausible, therefore, that the fit of the bi-directional Random
Multiformity and Extreme Multiformity models is driven
by the paths they have in common with RM of CUD and
EM of CUD, respectively. Secondly, the CUD causes MDD
fits better than the MDD causes CUD model. Although
this difference is not substantial, the fit of the MDD causes
CUD model may reflect that Direction of Causation models are difficult to distinguish when modes of inheritance
of the disorders are similar (Heath et al. 1993). In the current study, this may be because both disorders are mainly
influenced by A and E, rather than by different etiological factors (e.g. A C E vs. A E). Lastly, the MDD causes
CUD model, along with all other models with a direction
of effect from MDD to CUD, was a substantially poorer fit
than the Saturated Model.
It is unclear, however, which of the two best-fitting
models is more likely. The CUD causes MDD model
assumes that the liability to develop MDD symptoms
increases continuously, as the risk of CUD increases. The
threshold in this model does not equal a sudden increase
in risk, which means that even sub-threshold increases in
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liability to CUD have a causal influence on the liability
to develop MDD (Rhee et al. 2004). On the other hand,
the RM of CUD model assumes that the risk of MDD
symptoms increases discontinuously, once the threshold
on the CUD liability has been passed (i.e. an individual
has reached a liability high enough to develop the disorder). An additional difference between the models is their
assumption about etiological processes. The causal model
assumes that any causal processes occur at the level of
the liability (Rhee et al. 2004), while the RM models
remain agnostic about the way in which one disorder
leads to symptoms of the other.
Despite some differences, the RM of CUD and CUD
causes MDD models are not incompatible. Causality may
play a role, and the good fit of the RM of CUD model may
indicate that the causal influences on the risk of MDD
only occur at higher levels of CUD risk (i.e. post-threshold). Additionally, it is likely that there are shared etiological factors between CUD and MDD. Evidence from
twin (Fu et al. 2002; Lynskey et al. 2004) and molecular
genetic studies (Bobadilla et al. 2013; Sherva et al. 2016;
Hodgson et al. 2016) suggests that there are genetic factors influencing both cannabis involvement and MDD.
There is also a plethora of environmental factors that
act as risk factors for both (e.g. Fergusson and Horwood
1997; Feingold et al. 2014). Overall, the almost identical
fit of both models may indicate that there are thresholddependent causal links from CUD to MDD, which occur
at the level of liability.
This interpretation is compatible with several findings. Risk factors for CUD, such as heavy cannabis use,
are likely to exert an environmental and genetic effect
on MDD. Heavy cannabis use can alter various domains
of cognitive functioning, such as attention and memory
(Solowij 2002), and thereby affect daily functioning and
potentially create circumstances in which individuals are
more likely to develop MDD. For instance, cannabis use
impacts negatively on educational attainment (Lynskey
and Hall 2000), which in turn may affect emotional wellbeing. Environmental effects may also manifest themselves through changes in brain structure and function.
Heavy cannabis users show a decrease in amygdala volumes (Yucel et al. 2008), which is also the case in unmedicated patients with MDD (Hamilton et al. 2008).
Furthermore, the endocannabinoid system, primary site
of the neurochemical effects of cannabis, is thought to be
involved in mood regulation (Ashton and Moore 2011).
Genes may modulate these environmental influences.
Lastly, the conclusion that causal processes may be at
work in individuals at high risk for CUD (e.g. high levels of cannabis use), also fits well with longitudinal studies which show that high levels of cannabis use are more
strongly associated with MDD than lower levels.
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Heritability estimates
The heritability estimates obtained from the models are
similar to other twin studies for MDD (Sullivan et al.
2000; Kendler et al. 2006b), and to studies on cannabis
abuse/dependence that included similar samples. Kendler
et al. (2006a) report a heritability estimate of 77% (95%
CI 46–93%) for DSM-IV cannabis abuse/dependence in a
sample of same-sex and opposite-sex twins with a mean
age of 28.2. While a meta-analysis on twin studies reporting at least 1 symptom of abuse/dependence, presents lower
heritability estimates [males: 54.4% (95% CI 37.9–64.9%),
females: 58.5 (95% CI 44.2%–72.9%), Verweij et al. 2010],
the higher estimate obtained in the current may be related
to differences in sampling or the definition of problematic
cannabis use.
Limitations and future research
Difficulties in differentiating between models were a known
limitation, based on previous studies. Rhee et al. (2004)
provide a detailed discussion of general limitations of the
NK model fitting approach. Although Rhee et al. (2004)
demonstrated that the NK approach to discriminating
between different models of co-morbidity is valid; they
did so with a large simulated sample and still noted several
challenges. They highlighted that it is particularly difficult
to discriminate between the multiformity and the correlated
liabilities model classes, which was also the case in the
current sample. Additionally, Rhee et al. (2004) pointed out
that discrimination within subclasses of models (e.g. RM
vs. RM of CUD) is also problematic. In the current analyses, the difference within subclasses was often not more
than 3 AIC. It may be beneficial to replicate the study with
larger samples or use meta-analysis to examine whether
differences between models become more distinct. Replication of our results would be useful to explore whether the
results of the current study are cohort-specific or generalize
across cohorts, but is outside the scope of the present study.
One limitation of the current study is that sex differences have not been taken into account. The prevalence of
MDD and CUD did differ between males and females in
the analysis sample, but currently all co-morbidity models
can only be fitted on contingency tables, in which it was
not possible to specify separate thresholds for males and
females. The alternative approach of fitting separate models for males and females was not feasible due to lack of
power. However, there are currently no grounds to assume
that different co-morbidity models would explain co-morbid cases in males and females. For instance, Agrawal
et al. (2010) examined the co-morbidity between cannabis
and tobacco use, and fitted separate models for male and
female twins. They found that model fits were very similar
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for both sexes. It may be an interesting avenue for future
research to explore sex differences in larger samples or
using meta-analysis.
Given that one of the best-fitting models makes assumptions about causality, it is also an important limitation that
the data are retrospective and age of onset was not considered in the analyses. Using retrospective data has several
disadvantages (see e.g. Coughlin 1990), but for the current
analyses the most pertinent drawback is that longitudinal
data would be better suited to test direction of causation.
Beyond twin models, recent molecular genetic methods
also offer an interesting avenue to assess causality (see
Pickrell et al. 2016).
Finally, the discordant twin results are difficult to interpret due to the small number of MZ twin pairs discordant
for CUD. The results are in contrast to study results in Lynskey et al. (2004) and in line with those in Lin et al. (1996),
but overall they are not entirely comparable to either: both
studies examined cannabis dependence rather than CUD.
To conclusively examine whether causal processes can be
excluded using the discordant twin method, larger sample
sizes would be necessary. However, for the purposes of
the current study, the main intention was establishing that
causal processes could not be ruled out within the current
data set.
A valuable next step would be the inclusion of known
confounding factors. As mentioned above, Fu et al. (2002)
have found that antisocial personality disorder, while
being comparatively rare (Coid et al. 2006) and therefore
unlikely to explain most co-morbid cases, is a significant
confounder in the genetic relationship between cannabis
dependence and MDD. Moreover, longitudinal studies have
highlighted that cannabis users and non-users differ on a
number of domains (Fergusson and Horwood 1997; Feingold et al. 2014). As such, it would be valuable to examine
which models provide the best fit when confounding factors
are included.

Conclusion
Overall, the model fitting approach has been a beneficial indicator of the likely relationship between CUD and
MDD. While it was not possible to statistically differentiate between the two best fitting models RM of CUD and
CUD causes MDD, they both seem to indicate that the
direction of influence goes from CUD to MDD. Combined,
the models suggest that CUD risk factors may cause MDD
symptoms, but only in higher risk individuals. In addition, several models can be statistically excluded: CUD
and MDD are not likely to be co-morbid by chance, arise
from the same risk factors, or be due to a liability separate
from the pure form of the disorders. The fact that a Random
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Multiformity model is the best fitting model is remarkable,
because this model is not widely reported. Replications on
larger samples would be beneficial in order to help differentiate between models with subtle differences.
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